Skip to main content

Table 1 Patient and treatment characteristics

From: Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging (19F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer

  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (years) 66 60 31 63 63
Sex Female Male Female Male Male
BMI (kg/m2) 20.9 24.2 29.3 19.4 25.4
History of oncologic treatment of the liver Hemihepatectomy Radio-embolisation Partial hepatectomy None None
TAS-102 dosage 50 mg b.i.d. 65 mg b.i.d. 55 mg b.i.d. 60 mg b.i.d. 70 mg b.i.d.
Cycle number Cycle 2 day 8 Cycle 1 day 9 Cycle 1 day 9 Cycle 1 day 9 Cycle 1 day 9
Time of response evaluation according to RECIST After 4 cycles TAS-102 After 3 cycles TAS-102 After 3 cycles TAS-102 After 3 cycles TAS-102 After 3 cycles TAS-102
Time to first disease progression (progression-free survival) 3.7 months 2.8 months 2.8 months 2.8 months 2.8 months
Time between oral intake of TAS-102 and first MRS examination 30 min 90 min 105 min 150 min 60 min
Timing of both localised CSI scans 14.24 min 14.24 min 14.24 min 14.24 min 14.24 min
  1. Abbreviations: BMI body mass index, b.i.d. bi-daily, CSI chemical shift imaging, min minutes, MRS magnetic resonance spectroscopy, RECIST Response Evaluation Criteria In Solid Tumours, TAS-102 trifluridine/tipiracil